An APRIL to remember: Novel TNF ligands as therapeutic targets

Stacey R. Dillon, Jane A. Gross, Stephen M. Ansell, Anne J. Novak

Research output: Contribution to journalReview articlepeer-review

263 Scopus citations


Since their discovery in 1998, the two TNF family members APRIL and BLyS/ BAFF have received increasing attention. In addition to regulating normal B-cell development and immune responses, these molecules might be crucial in a diverse set of diseases, including autoimmunity and cancer. Although more has been published about the general biology of BLyS/BAFF than that of APRIL, many recent articles have described novel APRIL biology. Here we focus on APRIL, exploring its normal and pathological functions, and comparing the therapeutic molecules currently under development that target BLyS/BAFF alone, or APRIL and BLyS/BAFF together.

Original languageEnglish (US)
Pages (from-to)235-246
Number of pages12
JournalNature Reviews Drug Discovery
Issue number3
StatePublished - Mar 1 2006

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'An APRIL to remember: Novel TNF ligands as therapeutic targets'. Together they form a unique fingerprint.

Cite this